{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004444","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.863276+00:00","generated_at":"2026-06-13T10:23:56.215017+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BioCryst principal accounting officer resigns; CFO to serve as interim","bullets":["Michael Jones, Principal Accounting Officer, resigns effective July 7, 2023; will stay as Exec. Director Finance through April 2024.","Resignation not due to any disagreement on company operations, policies, or practices.","Board appoints CFO Anthony Doyle as interim Principal Accounting Officer effective July 10, 2023.","Doyle's compensation unchanged; no family relationships or transactions disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004444","json":"https://secwatch.observer/filing/0001171843-23-004444.json","markdown":"https://secwatch.observer/filing/0001171843-23-004444.md","text":"https://secwatch.observer/filing/0001171843-23-004444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/f8k_071123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:23:56.215017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05faab69bc","claim":"Anthony Doyle was appointed as Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"c1ffe18064","claim":"Michael L. Jones resigned as Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), informed the Company of his intention to resign from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}